Detalhe da pesquisa
1.
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
J Med Virol
; 95(1): e28157, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117402
2.
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Br J Cancer
; 125(4): 582-592, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34088988
3.
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
J Cell Mol Med
; 24(5): 2968-2980, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31967735
4.
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
J Cell Mol Med
; 24(3): 2145-2156, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31943762
5.
Inhibition of the deubiquitinase USP10 induces degradation of SYK.
Br J Cancer
; 122(8): 1175-1184, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32015510
6.
Repurposing of Kinase Inhibitors for Treatment of COVID-19.
Pharm Res
; 37(9): 167, 2020 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32778962
7.
Current therapies under investigation for COVID-19: potential COVID-19 treatments.
Can J Physiol Pharmacol
; 98(8): 483-489, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32640179
8.
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Br J Haematol
; 187(4): 488-501, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31309543
9.
Inhibition of USP10 induces degradation of oncogenic FLT3.
Nat Chem Biol
; 13(12): 1207-1215, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28967922
10.
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
Blood
; 125(20): 3133-43, 2015 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25833960
11.
Structure-guided development of covalent TAK1 inhibitors.
Bioorg Med Chem
; 25(3): 838-846, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28011204
12.
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Bioorg Med Chem
; 25(4): 1320-1328, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28038940
13.
Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia.
Haematologica
; 106(2): 605-609, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299905
14.
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
Nat Rev Cancer
; 7(5): 345-56, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17457302
15.
Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.
Arch Toxicol
; 88(12): 2233-42, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25331939
16.
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.
Cancers (Basel)
; 16(7)2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38610997
17.
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside".
Biochemistry
; 57(5): 477-478, 2018 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29188995
18.
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
Blood
; 117(12): 3421-9, 2011 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21233313
19.
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Cancer Cell
; 7(2): 129-41, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15710326
20.
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.
MedComm (2020)
; 4(3): e254, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37193304